1. A pharmaceutical combination comprising (i) a MET tyrosine kinase inhibitor and (ii) an EGFR tyrosine kinase inhibitor, or a pharmaceutically acceptable salt thereof, respectively, or a prodrug thereof, respectively, and at least one pharmaceutically acceptable carrier. A pharmaceutical combination according to claim 1 for the simultaneous, separate or sequential use of components (i) and (ii). 3. The pharmaceutical combination of claim 1 in the form of a fixed combination. The pharmaceutical combination of claim 1 in the form of a dosage form or in a kit consisting of parts for combined administration, wherein the EGFR tyrosine kinase inhibitor and MET tyrosine kinase inhibitor can be administered independently at the same time or separately at time intervals, in particular if the indicated time intervals make possible the joint activity of the participants in the combination. 5. The pharmaceutical combination according to any one of paragraphs. 1-4, where the EGFR tyrosine kinase inhibitor is erlotinib, gefitinib, lapatinib, canterinib, pelitinib, neratinib or cetuximab； and where the MET inhibitor is a compound of the formula: or a pharmaceutically acceptable salt or prodrug thereof, respectively. The combination according to claim 1, containing an additional coagent or a pharmaceutically acceptable salt or prodrug thereof. The combination according to claim 1, comprising an amount that is jointly therapeutically effective against a disease mediated by the tyrosine kinase activity of EGFR and / or tyrosine kinase activity of MET, in particular a malignant tumor, comprising as participants in the combination (i) an EGFR tyrosine kinase inhibitor and (ii) an inhibitor tyrosine kinases MET, or, accordingly, their pharmaceutical1. Фармацевтическая комбинация, содержащая (i) ингибитор тирозинкиназы МЕТ и (ii) ингибитор тирозинкиназы EGFR, или его фармацевтически приемлемую соль, соответственно, или его пролекарство, соответственно, и, по меньшей мере, один фармацев
